[Special Stock] MGen Solution Achieves World-First Success in Transplanting Genetically Modified Pig Heart into Human...Technology Spotlighted
Emgen Solution is showing strong performance following news of a successful surgery transplanting a genetically modified pig heart into a patient with heart disease.
As of 9:57 AM on the 25th, Emgen Solution is trading at 2,500 KRW, up 5.49% from the previous day.
In January last year, researchers at the University of Maryland School of Medicine achieved the world's first successful pig heart transplant surgery, and they have made further progress. On the 22nd (local time), the University of Maryland School of Medicine announced, "The patient who underwent the transplant surgery on the 20th is recovering and is breathing independently without the aid of any support devices."
Accordingly, the related industry expects a paradigm shift in organ transplantation. This is because it has been proven through two surgeries that the major obstacle of early acute rejection, considered the biggest challenge in transplantation, has been overcome.
The patient who received the pig heart transplant this time was suffering from end-stage heart disease. Due to multiple complex conditions, the patient was rejected by all heart transplant programs. The U.S. Food and Drug Administration (FDA) granted emergency approval for this transplant under the "compassionate use" procedure, which allows experimental procedures for critically ill patients.
Meanwhile, Emgen Solution successfully developed the world's first cloned pig that secretes human insulin using CRISPR gene-editing technology. They also produced the first immunodeficient pig in Korea.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Emgen Solution plans to proceed with domestic clinical trials involving actual diabetic patients depending on the results of xenogeneic islet transplantation experiments in monkeys scheduled for the first half of next year. Additionally, they intend to establish a transgenic pig mass production system at a new research facility within the Osong Bio-Science Complex, turning it into a specialized production base.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.